title: Algorithm for pre-emptive glycopeptide treatment in patients with haematologic malignancies and an Enterococcus faecium bloodstream infection.
abstract: BACKGROUND
  Nowadays Enterococcus faecium has become one of the most emerging and challenging nosocomial pathogens. The aim of this study was to determine risk factors in haematology patients who are at risk of an Enterococcus faecium bloodstream infection (BSI) and should be considered for pre-emptive glycopeptide treatment. With these identified risk factors a prediction model can be developed for clinical use.
  
  
  METHODS
  Retrospectively clinical and microbiological data in 33 patients with an E. faecium BSI were compared to 66 control patients during a 5-year period at the haematology ward. Multivariate logistic regression was used to explore the independent risk factors and a prediction model was developed to determine the risk of an E. faecium BSI.
  
  
  RESULTS
  E. faecium BSIs were found to be associated with high mortality rates. Independent risk factors for E. faecium BSI were colonization with E. faecium 30 days prior to blood culture (OR 5.71; CI 1.7-18.7), combination of neutropenia and abdominal focus (4.37; 1.4-13.4), age > 58 years (4.01; 1.3-12.5), hospital stay prior to blood culture > 14 days (3.55; 0.98-12.9) and CRP (C-reactive protein) level >125 mg/L (4.37; 1.1-10.2).
  
  
  CONCLUSIONS
  Using data from this study, risk stratification for the development of an E. faecium BSI in patients with haematological malignancies is possible. Pre-emptive treatment should be considered in those patients who are at high risk. Using a prediction model as designed in this study, antibiotic stewardship in terms of prudent use of glycopeptides can be improved and might be helpful in controlling further spread of VRE (vancomycin resistant enterococci).
authors.affiliation: Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. x.w.zhou@umcg.nl.
authors.forename: Xuewei
authors.initials: X
authors.lastname: Zhou
authors.forename: Jan P
authors.initials: JP
authors.lastname: Arends
authors.forename: Lambert Fr
authors.initials: LF
authors.lastname: Span
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Friedrich
references.citation: Infect Control Hosp Epidemiol. 1995 Dec;16(12):680-5
references.pmid: 8683085
references.citation: Antimicrob Agents Chemother. 2005 Jul;49(7):2693-700
references.pmid: 15980338
references.citation: Clin Infect Dis. 1996 Oct;23(4):767-72
references.pmid: 8909842
references.citation: J Infect. 2006 Oct;53(4):266-73
references.pmid: 16388852
references.citation: Eur J Clin Microbiol Infect Dis. 2011 Jan;30(1):103-8
references.pmid: 20711795
references.citation: Eur J Haematol. 2007 Sep;79(3):226-33
references.pmid: 17655696
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2918-26
references.pmid: 15254061
references.citation: J Hosp Infect. 2006 May;63(1):14-26
references.pmid: 16563562
references.citation: Clin Infect Dis. 1995 Feb;20(2):296-301
references.pmid: 7742433
references.citation: Emerg Infect Dis. 2001 Mar-Apr;7(2):183-7
references.pmid: 11294702
references.citation: J Clin Microbiol. 1998 Dec;36(12):3734-6
references.pmid: 9817912
references.citation: Clin Microbiol Infect. 2013 Sep;19(9):860-8
references.pmid: 23039210
references.citation: Intensive Care Med. 2010 Aug;36(8):1394-402
references.pmid: 20232045
references.citation: Clin Microbiol Rev. 1994 Oct;7(4):462-78
references.pmid: 7834601
references.citation: Clin Infect Dis. 2012 Sep;55(6):764-70
references.pmid: 22693346
references.citation: Infect Control Hosp Epidemiol. 1999 Oct;20(10):660-3
references.pmid: 10530642
references.citation: J Antimicrob Chemother. 2008 Dec;62(6):1401-6
references.pmid: 18812427
references.citation: Curr Opin Microbiol. 2006 Oct;9(5):454-60
references.pmid: 16880002
references.citation: Crit Care Med. 2008 Jan;36(1):296-327
references.pmid: 18158437
references.citation: J Hosp Infect. 2000 Jun;45(2):135-44
references.pmid: 10860690
references.citation: BMC Infect Dis. 2011 Mar 31;11:80
references.pmid: 21453466
references.citation: Eur J Clin Microbiol Infect Dis. 2010 Jan;29(1):107-14
references.pmid: 19916034
references.citation: Antimicrob Agents Chemother. 1994 Jun;38(6):1363-7
references.pmid: 8092838
references.citation: Clin Infect Dis. 2006 Mar 15;42(6):739-46
references.pmid: 16477546
references.citation: Clin Microbiol Infect. 2011 Jul;17(7):1078-83
references.pmid: 20946408
references.citation: Clin Microbiol Infect. 2013 Feb;19(2):141-60
references.pmid: 22117544
references.citation: FEMS Immunol Med Microbiol. 2008 Apr;52(3):297-308
references.pmid: 18279340
references.citation: Rev Infect Dis. 1991 Jul-Aug;13(4):600-5
references.pmid: 1925276
references.citation: Nat Rev Microbiol. 2012 Mar 16;10(4):266-78
references.pmid: 22421879
references.citation: Clin Infect Dis. 1995 May;20(5):1126-33
references.pmid: 7619987
references.citation: Euro Surveill. 2008 Nov 20;13(47):
references.pmid: 19021959
references.citation: Clin Microbiol Infect. 2007 Mar;13(3):316-9
references.pmid: 17391388
references.citation: Infection. 2009 Dec;37(6):540-3
references.pmid: 19669085